Pharma & biotech

Danish reimbursement committee submits diabetes reassessment proposal for feedback

The Danish Medicines Agency’s committee responsible for recommending what medicines gain rebates is looking into diabetes medicines – excluding insulin. A hearing round for industry feedback is slated to end early next year.
GLP-1 analogs like Novo Nordisk's Rybelsus (depicted) for the treatment of type 2 diabetes are so expensive than they should only be used for patients who have tried other options first | Photo: Novo Nordisk / PR
GLP-1 analogs like Novo Nordisk's Rybelsus (depicted) for the treatment of type 2 diabetes are so expensive than they should only be used for patients who have tried other options first | Photo: Novo Nordisk / PR
by albert rønning-andersson, translated by daniel pedersen

In March, the Danish Medicines Agency chose to go down a different path from what its reimbursement committee had recommended in a reassessment of the reimbursement of insulin prescribed to treat diabetes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs